Autologous and allogeneic stem cell transplantation in multiple myeloma
Multiple myeloma is still an incurable disease. The standard conventional chemotherapy comprises melphalan and prednisone (MP). Combination chemotherapy regimens could not improve the median survival of 36 months observed with MP. In the French IFM90 study, HD therapy with TBI plus melphalan 140 mg/...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2000
|
| In: |
Bone marrow transplantation
Year: 2000, Volume: 25, Pages: 25-26 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/sj.bmt.1702348 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bmt.1702348 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/1702348 
|
| Author Notes: | H. Goldschmidt, G. Egerer and A.D. Ho |
| Summary: | Multiple myeloma is still an incurable disease. The standard conventional chemotherapy comprises melphalan and prednisone (MP). Combination chemotherapy regimens could not improve the median survival of 36 months observed with MP. In the French IFM90 study, HD therapy with TBI plus melphalan 140 mg/m2 was shown to prolong overall survival and progression-free survival compared to conventional treatment. Nonetheless, most patients eventually succumb due to disease progression. Allogeneic transplantation may induce long-term remissions and even cure, but is hampered by a high transplantation-related mortality (TRM). Currently, efforts are made to reduce this TRM and to evaluate the graft-versus-myeloma effect. |
|---|---|
| Item Description: | Gesehen am 01.03.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/sj.bmt.1702348 |